Does maximal androgen blockade (MAB) improve survival? A critical appraisal of the evidence.
The conflicting data surrounding the benefit of total androgen blockade compared to monotherapy for metastatic prostate cancer is reviewed. The recent Lancet meta-analysis is critically appraised. A sensitivity analysis of the studies is presented.
Department of Surgery, University of Toronto, Sunnybrook Health Science Center, Toronto, Ontario.
Laurence H.
LH
Klotz
Toni
T
Newman